Skip to main content

Advertisement

Table 6 Comparison of the percentages of B cell subsets in IFN-β-treated MS patients stratified to the NEDA or EDA groups

From: Long-term use of interferon-β in multiple sclerosis increases Vδ1Vδ2Vγ9 γδ T cells that are associated with a better outcome

  MS w/IFN-β HCs (n = 44) p value (K-W test) padj value
NEDA (n = 8) EDA (n = 13) NEDA vs. HCs EDA vs. HCs NEDA vs. EDA
Naïve (CD27IgD+) 57.9 (46.6–64.6) 47.3 (29.4–54.8) 51.8 (41.4–60.6) NS
Memory (CD27+) 12.2 (8.75–18.3) 8.87 (6.42–14.0) 22.7 (16.9–29.9) < 0.001 0.009 < 0.001 NS
 CS+ Memory (CD27+IgD) 10.8 (6.28–16.5) 7.74 (5.96–13.2) 18.8 (14.4–25.2) < 0.001 0.017 < 0.001 NS
 CS Memory (CD27+IgD+) 1.66 (0.96–3.09) 0.96 (0.70–1.25) 3.49 (2.49–4.67) < 0.001 NS (0.076) 0.002 NS
Plasmablasts (CD38highCD20) 0.37 (0.28–0.55) 0.32 (0.22–0.58) 0.37 (0.24–0.67) NS
Transitional (CD24highCD38high) 6.73 (2.75–14.9) 4.56 (1.32–7.02) 3.14 (2.32–4.45) NS
  1. Values are the median (IQR). Percentages of each population in total B cells are shown
  2. p values (K-W test) were obtained by Kruskal-Wallis analyses, and if they were statistically significant, then padj values were calculated using multivariate linear regression analyses adjusted for age and sex
  3. CS+ class-switched, CS non-class-switched, EDA evidence of disease activity, HCs healthy controls, IFN-β interferon-β, IQR interquartile ranges, K-W Kruskal-Wallis, MS multiple sclerosis, NEDA no-evidence of disease activity, NS not significant, w/ with